FujiLAM用于HIV感染者结核检测的成本效果
研究用微模拟模型评估住院HIV感染者三种结核检测策略的成本效果,队列匹配两国临床试验。与Xpert+AlereLAM相比,Xpert+FujiLAM在南非和马拉维均增加0.2年预期寿命且具成本效果。
要点
- Xpert+FujiLAM较Xpert+AlereLAM在南非和马拉维均增加0.2年预期寿命。
- Xpert+FujiLAM在两国均具成本效果,且优于序贯检测和CD4分层策略。
- 全国推广FujiLAM使受检者5年医疗费用增加3.5%(南非)和4.7%(马拉维)。
核心结论
- 在住院HIV感染者中,Xpert+FujiLAM检测结核可能增加预期寿命,并在南非和马拉维当前预期价格下具成本效果。
研究设计与样本
- 采用微模拟模型预测三种检测策略的临床与经济结局,模型队列匹配一项两国临床试验。
主要发现
- 与Xpert+AlereLAM相比,Xpert+FujiLAM在南非和马拉维使受检者预期寿命增加0.2年。
- Xpert+FujiLAM在两国均具成本效果,对全部患者检测相较序贯检测和CD4分层策略仍具成本效果。
- FujiLAM使受检者5年医疗费用增加3.5%(南非)和4.7%(马拉维),主要反映存活者持续的HIV治疗费用。
关键数值与推荐
- CD4<200 cells/µL者中Xpert/Xpert+AlereLAM/Xpert+FujiLAM的诊断产出为33%/62%/70%。
- CD4≥200 cells/µL者中上述三种策略诊断产出为33%/35%/47%。
- Xpert/AlereLAM/FujiLAM费用为南非15/3/6美元、马拉维25/3/6美元。
- 成本效果阈值:南非<940美元/挽救生命年,马拉维<750美元/挽救生命年。
临床怎么用
- 对住院HIV感染者,可考虑在Xpert基础上加做尿FujiLAM以替代AlereLAM,两国当前价格下具成本效果。
局限性
- 诊断产出取自回顾性研究,成本效果结论基于模型外推,作者建议在临床实践环境中进一步评估FujiLAM。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A novel urine lipoarabinomannan assay (FujiLAM) has higher sensitivity and higher cost than the first-generation AlereLAM assay. We evaluated the cost-effectiveness of FujiLAM for tuberculosis testing among hospitalized people with human immunodeficiency virus (HIV), irrespective of symptoms. METHODS: We used a microsimulation model to project clinical and economic outcomes of 3 testing strategies: (1) sputum Xpert MTB/RIF (Xpert), (2) sputum Xpert plus urine AlereLAM (Xpert+AlereLAM), (3) sputum Xpert plus urine FujiLAM (Xpert+FujiLAM). The modeled cohort matched that of a 2-country clinical trial. We applied diagnostic yields from a retrospective study (yields for Xpert/Xpert+AlereLAM/Xpert+FujiLAM among those with CD4 <200 cells/µL: 33%/62%/70%; among those with CD4 ≥200 cells/µL: 33%/35%/47%). Costs of Xpert/AlereLAM/FujiLAM were US$15/3/6 (South Africa) and $25/3/6 (Malawi). Xpert+FujiLAM was considered cost-effective if its incremental cost-effectiveness ratio (US$/year-of-life saved) was <$940 (South Africa) and <$750 (Malawi). We varied key parameters in sensitivity analysis and performed a budget impact analysis of implementing FujiLAM countrywide. RESULTS: Compared with Xpert+AlereLAM, Xpert+FujiLAM increased life expectancy by 0.2 years for those tested in South Africa and Malawi. Xpert+FujiLAM was cost-effective in both countries. Xpert+FujiLAM for all patients remained cost-effective compared with sequential testing and CD4-stratified testing strategies. FujiLAM use added 3.5% (South Africa) and 4.7% (Malawi) to 5-year healthcare costs of tested patients, primarily reflecting ongoing HIV treatment costs among survivors. CONCLUSIONS: FujiLAM with Xpert for tuberculosis testing in hospitalized people with HIV is likely to increase life expectancy and be cost-effective at the currently anticipated price in South Africa and Malawi. Additional studies should evaluate FujiLAM in clinical practice settings.
引用
- Reddy KP, Denkinger CM, Broger T, et al. Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 33200169. doi:10.1093/cid/ciaa1698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。